Improvement in Pancreatic and Colorectal Cancer Therapies

Improvement in medicine has led to advances in the detection, prevention, and analysis of cancer for patients with inherited risks of GI cancer, particularly genetic colorectal cancer and genetic pancreatic cancer.

The current practices for identifying, evaluating, and managing patients with suspected genetic colorectal cancer and pancreatic cancer risk is improving. The impact of next-generation sequencing technologies in the clinical diagnosis of hereditary gastrointestinal cancer and in discovery efforts of novel genes linked to familial cancer risk is increasing. Emerging targeted therapies that may play a particularly important role in the treatment of patients with hereditary forms of colorectal cancer and pancreatic cancer are giving good results.

Recent innovations in genetic medicine and next-generation sequencing technologies have led to tremendous advances in the understanding of the role that genetics plays in carcinogenesis.

The availability of novel diagnostic, risk-reducing, and therapeutic strategies that exist for patients with hereditary risk for colorectal or pancreatic cancer. It is imperative that clinicians be vigilant about evaluating patients for hereditary cancer syndromes. Continuing to advance genetics research in hereditary gastrointestinal cancers will allow for more progress to be made in personalized medicine and prevention.

Colorectal cancer remains the fourth most incident cancer and the second most common cause of cancer-related mortality. Over the past decade, scientific knowledge about the genetics of colorectal cancer has grown exponentially, and the coming years promise continued advances in the identification, management, and understanding of patients with hereditary predisposition to colorectal cancer.

There is no single gene that is responsible for hereditary or familial pancreatic cancer risk. Rather, there are multiple hereditary cancer syndromes and associated genes which confer an increased lifetime risk of pancreatic cancer.

Advances have also been made in the realm of aspirin chemoprevention for patients with hereditary colorectal cancer.

For more details related to Improvement in Pancreatic cancer therapies, please visit- https://gastroenterology.gastroconferences.com/